RecruitingAlzheimer Disease
DORA and LP in Alzheimer's Disease Biomarkers
Eligible age
65+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ Male or female.
- ✓ Any race or ethnicity.
- ✓ Participants must be age ≥ 65 years and able to sign informed consent.
- ✓ Global Clinical Dementia Rating (CDR) 0.
- ✓ Willing and able to undergo study procedures.
You may not qualify if…
- ✕ History or reported symptoms suggestive of restless legs syndrome, narcolepsy, or parasomnia.
- ✕ STOP-Bang score \>6 for participants without PAP.
- ✕ Untreated sleep apnea AHI\>15
- ✕ Poorly treated sleep apnea due to noncompliance or an AHI ≥ 10.
- ✕ \- PAP compliance is defined as ≥ 4 hours per night \>70% of the nights.
- ✕ Plasma p-Tau217/np-Tau217% \<2.5
- ✕ Stroke.
- ✕ History of renal impairment
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT06274528 · last updated 2026-05-05